Compare QSI & CION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QSI | CION |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 527.0M |
| IPO Year | N/A | N/A |
| Metric | QSI | CION |
|---|---|---|
| Price | $1.28 | $9.86 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 3 | 1 |
| Target Price | $2.63 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 4.8M | 426.0K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 15.31% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.49 |
| Revenue | $3,177,000.00 | ★ $244,923,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $159.68 | N/A |
| P/E Ratio | ★ N/A | $19.78 |
| Revenue Growth | ★ 40.20 | N/A |
| 52 Week Low | $0.95 | $8.51 |
| 52 Week High | $5.77 | $12.71 |
| Indicator | QSI | CION |
|---|---|---|
| Relative Strength Index (RSI) | 47.94 | 53.02 |
| Support Level | $1.07 | $9.43 |
| Resistance Level | $1.33 | $10.17 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 77.69 | 53.80 |
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.